| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $228,711 ) |
| | 2024 | 2024 | VINCERE BIOSCIENCES, INC | 245 MAIN ST FL 2 | CAMBRIDGE | MA | 02142-1064 | MIDDLESEX | USA | R43NS127693 | In vivo Evaluation of USP30 Inhibitors in Models Relevant to Parkinson's Disease | 001 | 2 | NIH | 8/16/2024 | $228,711 |
| | 2024 | 2023 | VINCERE BIOSCIENCES INC | 245 MAIN ST | CAMBRIDGE | MA | 02142-1064 | MIDDLESEX | USA | R43NS127693 | In vivo Evaluation of USP30 Inhibitors in Models Relevant to Parkinson's Disease | 000 | 1 | NIH | 10/30/2023 | $0 |
| | 2024 | 2022 | VINCERE BIOSCIENCES, INC | 245 MAIN ST FL 2 | CAMBRIDGE | MA | 02142-1064 | MIDDLESEX | USA | R43AG079697 | Evaluation of USP30 small molecule inhibitors in models relevant to Cardiac Aging | 000 | 1 | NIH | 4/5/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $470,514 ) |
| | 2023 | 2023 | VINCERE BIOSCIENCES INC | 245 MAIN ST | CAMBRIDGE | MA | 02142-1064 | MIDDLESEX | USA | R43NS127693 | In vivo Evaluation of USP30 Inhibitors in Models Relevant to Parkinson's Disease | 000 | 1 | NIH | 9/18/2023 | $470,514 |
| | 2023 | 2022 | VINCERE BIOSCIENCES INC | 245 MAIN ST | CAMBRIDGE | MA | 02142-1064 | MIDDLESEX | USA | R43AG079697 | Evaluation of USP30 small molecule inhibitors in models relevant to Cardiac Aging | 000 | 1 | NIH | 4/18/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $299,497 ) |
| | 2022 | 2022 | VINCERE BIOSCIENCES, INC. | 245 MAIN ST FL 2 | CAMBRIDGE | MA | 02142-1064 | MIDDLESEX | USA | R43AG079697 | Evaluation of USP30 small molecule inhibitors in models relevant to Cardiac Aging | 000 | 1 | NIH | 8/10/2022 | $299,497 |
|
| Issue Date FY: 2020 ( Subtotal = $251,987 ) |
| | 2020 | 2020 | VINCERE BIOSCIENCES, INC. | 245 MAIN ST FL 2 | CAMBRIDGE | MA | 02142-1064 | MIDDLESEX | USA | R43NS115255 | Discovery and Development of USP30 inhibitors as Disease-Modifying Therapy for Parkinson's disease. | 000 | 1 | NIH | 4/13/2020 | $251,987 |
|
|
